Home and US CAPEX places India on brink of bioCDMO breakthrough
Syngene expects benefits from big pharma’s China-plus-one strategy
Elevating Biomanufacturing Efficiency with N-1 Perfusion Technology
Global CDMO Trends: the 2024 outsourcing forecast
ADCs present compelling opportunity to deliver crucial drugs, particularly for oncology medications
Indian pharma adopts green initiatives with eco-friendly manufacturing processes to save environment
Indian CDMOs expand capacities with Syngene taking the lead
Biopharma manufacturing turbulence boosts inquiries for India-based providers
Navigating the Pharma Landscape
AI and ML is changing the game of drug discovery
